Steffan Joe @go_62036dc494e07
08 March, 07:45
DNA data storage market is anticipated to grow at an annualized rate of over 26% by 2035

Exponential increase in amount of digital data being generated, coupled to the limitations of conventional storage mediums, has created a need for sustainable storage options and DNA data storage has garnered significant interest as an alternative

London

Roots Analysis has announced the addition of DNA Data Storage Market, 2021-2035” report to its list of offerings.

DNA as a data storage medium helps eliminate the drawbacks inherent to the traditional storage methods, such as limited storage density, instability and limited life span, making it a potential storage option for future. However, exorbitant costs, slow speed of reading and writing DNA and vulnerability to mutations or errors, may act as a roadblock in the wider use of DNA as an effective data storage solution, which has prompted the stakeholders to focus on improvements in various steps involved in DNA data storage, including data encoding, DNA synthesis, preservation, data retrieval, and DNA sequencing.

To order this 240+ page report, which features 75+ figures and 90+ tables, please visit https://www.rootsanalysis....

Key Market Insights

Presently, more than 20 players claim to offer DNA Data Storage
Over 40% of these players are involved in offering technologies / services for coding and DNA writing (DNA synthesis), followed by those offering services for retrieval and DNA reading (29%). It is worth mentioning that 10 technology / service providers claim to have the required expertise to serve as one-stop-shops for all the DNA data storage steps.

Over 350 grants have been awarded to support research on DNA data storage, since 2016
Grants worth USD 517 million have been awarded to various organizations working in this domain during the period, 2016- 2021. Of these, 33% of the grants were awarded to support the research related to projects on DNA data storage, were / are being managed by NCI, followed by those managed by NIA (11%), NINDS (9%) and NIDDK (6%).

Over 900 patents have been filed / granted related to DNA data storage, since 2001
More than 50% of these patents were filed / granted in North America, followed by Europe (39%). In addition to the industry players, patents related to DNA data storage were also filed by academic institutes, such as Massachusetts Institute of Technology, Harvard University and University of Arkansas.

Partnership activity within this domain has grown significantly at a CAGR of 32%
More than 55% of the agreements were established in 2020. Majority of these deals were product development and commercialization agreements (21%), acquisitions (17%), technology licensing deals (17%), and manufacturing agreements (13%).

Funding and investment in this domain have increased significantly, highlighting the growing demand for DNA data storage systems
Around USD 1 billion was raised by companies, across various funding rounds in 2020. Majority of the companies raised significant capital through venture capital financing (~USD 417 million). It is worth highlighting that over 50% of the funding instances were reported by companies headquartered in North America, followed by Europe.

North America is expected to capture over 55% of the DNA data storage market share by 2035 Within North America, US is likely to capture the maximum share. Further, in terms of step involved in DNA based data storage, the coding and DNA writing step is likely to capture the highest market share (86%).

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis....

Key Questions Answered
 Who are the leading industry players involved in offering services or technologies related to DNA data storage?
 Which are the leading funding organizations providing grants for research on DNA data storage?
 How has the intellectual property landscape of DNA data storage evolved over the years?
 Which partnership models are commonly adopted by industry stakeholders offering services or technologies related to DNA data storage?
 What is the trend of capital investments in the DNA data storage market?
 How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the DNA data storage market has been analyzed across the following segments:
 DNA Data Storage Steps
 Coding and DNA Writing (DNA Synthesis)
 DNA Storage
 Retrieval and DNA Reading (DNA Sequencing)

 Geographical Regions
 North America
 Europe

The research includes detailed profiles of key players (listed below); each profile features an overview of the company, its financial information (if available), details on the technology / services offered, recent developments, and an informed future outlook.
 Agilent Technologies
 ATUM
 Codex DNA
 Gattaca Technologies
 GenScript
 Illumina
 Imagene
 Oxford Nanopore Technologies
 Synbio Technologies

For additional details, please visit
https://www.rootsanalysis....
or email salesrootsanalysis.com

You may also be interested in the following titles:
1. Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market, 2021-2030
2. Digital Solutions for Biomarkers Market, 2021-2030
3. AI-based Drug Discovery Market, 2020-2030

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnsonrootsanalysis.com
Steffan Joe @go_62036dc494e07
08 March, 07:36
CD-47 targeting therapeutics market is projected to grow at a CAGR of 42.9%, claims Roots Analysis

Upon realizing the potential of this novel target, industry stakeholders have initiated several R&D efforts focused on exploiting the use of CD47 as an effective biomarker for the diagnosis and treatment purposes.

Roots Analysis has announced the addition of “CD-47 Targeting Therapeutics Market, 2021-2035” report to its list of offerings.

In recent years, the focus of the research community has shifted towards the development of novel treatment modalities, such as T- cell immunotherapies, that exhibit high efficacy. CD-47, owing to its increased expression on the surface of cancer cells, has emerged as a cancer immune checkpoint biomarker.

To order this 190+ page report, which features 142+ figures, please visit https://www.rootsanalysis....

Key Market Insights

Over 75 CD-47 drug candidates are under various phases of development
52% of the pipeline candidates are currently in preclinical and discovery stages, while more than 48% therapies are being evaluated in clinical stages with most candidates being in early clinical stages (41.6%); 3.9% and 2.6% of clinical candidates being evaluated in phase II and phase III respectively.

~50 companies claim to be engaged in the development of CD-47 therapeutics, globally
Since 2015, 13 companies have been established in this domain. Further, around 44% of the industry stakeholders are small companies. In addition, majority (47%) of the CD-47 therapeutics developers are based in North America, primarily in the US.

Several clinical trials evaluating CD-47 targeting therapeutics have been registered worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 34.1%, during the period 2015-2020. Of the total, close to 13% of the studies have already been completed, followed by active trials that are actively recruiting patients (46.7%).

Partnership activity within this domain has increased at a CAGR of 25.7%, between 2016 and 2020
Clinical trial agreements emerged as the most popular type of partnership model adopted by industry stakeholders, followed by product development and commercialization agreements (25%), licensing agreements (25%), and services agreements (7.1%).

USD 3.3+ billion has been invested by both private and public investors
It is important to mention that, between 2016 and 2021, majority of the funding amount was raised through secondary offerings (46.5%), venture capital rounds (45%), IPO (15.6%) and debt financing (7.4%).

North America is anticipated to capture over 85% of the market share, by 2035
The market will be primarily driven by sales of CD-47 based therapeutics designed as biologics (over 60%), followed by those developed as small molecules (over 39%). Further, CD-47 based therapies targeting non-small cell lung cancer will capture the dominant share (23%) of the market (in terms of sales-based revenues); this trend is unlikely to change in the foreseen future.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis....

Key Questions Answered

 Who are the leading players engaged in the development of CD47 targeting therapeutics?
 Which are the key drugs being developed across early and late stages of development?
 Which companies are actively involved in conducting clinical trials for their therapeutics?
 What is the evolving trend related to the focus of publications related to CD47 targeting therapeutics?
 What kind of partnership models are commonly adopted by industry stakeholders?
 Who are the key investors in this domain?
 Who are the key opinion leaders / experts in this field?
 What are the evolving social media trends related to CD47 targeting therapeutics?
 What are the different initiatives undertaken by big pharma players for the development of CD47 therapeutics in the recent past?
 How is the current and future opportunity likely to be distributed across key market segments?

The financial opportunity within the CD-47 targeting therapeutics market has been analyzed across the following segments:
 Type of Molecule
 Biologics
 Small molecules

 Target Indications
 Acute Myeloid Leukemia
 Colorectal Neoplasms
 Diffuse-Large Cell Lymphoma
 Myelodysplastic Syndromes
 Non-Hodgkin Lymphoma
 Non-Small Cell Lung Cancer
 Oral Muscositis
 Ovarian Epithelial Cancer
 Small Cell Lung Cancer

 Key Players

 Key Geographical Regions
 US
 France
 Germany
 Italy
 Spain
 UK
 Australia
 China
 India
 Israel

The research includes detailed profiles of 10+ developers by (listed below); the profiles also feature an overview of the developer, its financial information (if available), recent developments and an informed future outlook.

 Abpro
 ALX Oncology
 Apmonia Therapeutics
 Arch Oncology
 Aurigene
 Bristol Myers Squibb
 EpicentRx
 Forty Seven
 ImmuneOncia Therapeutics
 ImmuneOnco Biopharmaceuticals
 Innovent Biologics
 KAHR Medical
 Light Chain Bioscience
 Morphiex
 Trillium Therapeutics

For additional details, please visit
https://www.rootsanalysis.... or email salesrootsanalysis.com

You may also be interested in the following titles:
1. RAS Targeting Therapies Market, 2021-2031
2. Squamous NSCLC Market, 2021-2031
3. Peptide Therapeutics Market, 2021-2031

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnsonrootsanalysis.com
Steffan Joe @go_62036dc494e07
01 March, 07:29
Site management organizations (SMO) market is projected to grow at an annualized rate of ~10% during the period 2021-2035.
In addition to being a time and cost intensive process, clinical trials are fraught with several challenges; considering the expertise available with site management organizations (SMOs) to conduct such studies in an efficient manner, trial sponsors are actively outsourcing their requirements

Roots Analysis is pleased to announce the publication of its recent study, titled, “Site Management Organizations (SMO) Market, 2021–2035.”

The study features an in-depth analysis, highlighting the capabilities of clinical trial site management service providers engaged in this domain. Amongst other elements, the report features:
 A detailed assessment of the current market landscape of companies offering clinical trial site management services.
 A competitiveness analysis of various service providers segregated into three peer groups based on location of their headquarters (North America, Europe, and Asia-Pacific and RoW). The companies were further distributed across the geographies, based on their employee count, into three categories, namely small (500 employees).
 Elaborate profiles of prominent players (shortlisted based on a proprietary criterion) that offer various clinical trial site management services, across North America, Europe and Asia-Pacific.
 An analysis of the partnerships that have been inked by stakeholders engaged in this domain, during the period 2016-2021 (till August).
 A detailed analysis of various investments received by players engaged in this domain during the period 2015-2021 (till August).
 An in-depth analysis of completed, ongoing and planned clinical studies during the period 2016-2021 (till August).
 An informed estimate of the annual demand for clinical study participants, based on various relevant parameters, for the period 2021-2035.
 A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below):
 Therapeutic Areas
 Oncological Disorders
 CNS Disorders
 Infectious Diseases
 Respiratory Disorders
 Cardiovascular Diseases
 Endocrine Disorders
 Gastrointestinal Disorders
 Musculoskeletal Diseases
 Immunological Disorders
 Others

 Trial Phases
 Phase I
 Phase II
 Phase III
 Phase IV

 Clinical Trial Components
 Site Management
 Onsite Monitoring
 Project Management
 Data Management
 Regulatory Affairs
 Logistics
 Quality Control
 Others

 Types of Interventions
 Therapeutics
 Devices
 Surgical Procedure

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Latin America
 MENA
 Rest of the World

 Transcripts of interviews held with the following senior level representatives of stakeholder companies
 Vinod Gyanchandani (Country Head - Clinical Operations, GDD Experts)
 Marisa Vico (Medical Director and Operations Manager, SMO – Dra. Marisa Vico)
 Eugene Winifred (Project Manager, Syncretic Clinical Research Services)

Key companies covered in the report
 FOMAT Medical Research
 Parexel
 Pharm-Olam
 Veristat
 WCCT Global
 Worldwide Clinical Trials
 CROMSOURCE
 Fidelis Research
 Scandinavian CRO
 TFS HealthScience
 Trialbee
 CMIC
 George Clinical
 Tigermed
 Veeda Clinical Research

For more information, please click on the following link:
https://www.rootsanalysis....

You may also be interested in the following titles:
1. Patient Recruitment and Retention Services Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030
2. Pharmaceutical Contract Research Services Market: Industry Trends and Global Forecasts, 2021-2030
3. Clinical Trial Planning and Design Services Market: Industry Trends and Global Forecasts, 2021-2030
4. Biospecimen Contract Research Services Market: Industry Trends and Global Forecast, 2021-2030
5. Biologics Fill / Finish Services Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnsonrootsanalysis.com
Steffan Joe @go_62036dc494e07
01 March, 07:23
The RNA targeting small molecules therapeutics market is estimated to be worth USD 8.3 billion in 2030.

In recent years, RNA’s potential as a target molecule for small molecules has been widely recognized; a number of players have developed proprietary technologies for direct and indirect RNA targeting, to treat a wide range of clinical conditions

Roots Analysis is pleased to announce the publication of its recent study, titled, “RNA Targeting Small Molecules Therapeutics Market”

The report features an extensive study of the current market landscape and future potential of the players engaged in the discovery and development of RNA targeting small molecules therapeutics. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features:

 An in-depth review of the market landscape of players that are engaged in the discovery and development of RNA targeting small molecules therapeutics being evaluated at both preclinical and clinical stages of development. It also includes a detailed landscape of developers active in this domain.
 An insightful analysis of the company competitiveness and investment landscape comparing the key players engaged in the domain of RNA targeting small molecules. Further, it includes start-ups and investment activity across different players.
 An analysis of the partnerships that have been inked by stakeholders in this area, during the period between 2017 and 2021.
 An in-depth analysis of investments made, during the period between 2015 and 2021, in companies that are engaged in the development of RNA targeting small molecules therapeutics.
 Elaborate profiles of key players engaged in the development of RNA targeting small molecules therapeutics.
 A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

 Type of Target Disease Indication
 Aniridia
 Breast Cancer
 Castrate-resistant Prostate Cancer
 Colorectal Cancer
 Cystic Fibrosis
 Crohn’s Disease
 Duchenne Muscular Dystrophy
 Dravet Syndrome
 HIV Infections
 Impaired Renal Function
 NSCLC
 Rheumatoid Arthritis
 Spinal Muscular Atrophy
 Ulcerative Colitis

 Type of Therapeutic Area
 Autoimmune Disorders
 Genetic Disorders
 Inflammatory Disorders
 Infectious Disorders
 Kidney Disorders
 Neurological Disorders
 Oncological Disorders
 Ophthalmic Disorders
 Rare Disorders
 Respiratory Disorders

 Type of Target Molecule
 CDKL5
 Cap Binding Complex
 Dystrophin Protein
 Estrogen Receptor Alpha
 G542X
 MNK1 / MNK2
 PAX6 Gene
 SMN2

 Type of Approach
 Indirect RNA Targeting- Epitranscriptomics
 mRNA Translation Modulation
 RNA Splicing Modification

 Route of Administration
 Oral
 Subcutaneous

 Key Geographical Regions
 North America
 Europe

Transcripts of interviews held with the following senior level representatives of stakeholder companies
 Clara Assouline (Business Development, Anima Biotech)
 Dominique Cheneval (Co-Founder and Chief Executive Officer, Novation Pharmaceuticals)

Key companies covered in the report
 Abivax
 AC Immune
 Arrakis Therapeutics
 eFFECTOR Therapeutics
 ELOXX Pharmaceuticals
 PTC Therapeutics
 H3 Biomedicine
 Ribometrix
 Skyhawk Therapeutics
 STORM Therapeutics

For more information, please click on the following link
https://www.rootsanalysis....

Other Recent Offerings
1. RAS Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
2. DNA Damage Response Targeting Therapeutics: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
3. HER2 Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnsonrootsanalysis.com
Steffan Joe @go_62036dc494e07
01 March, 07:12
The opportunity within the regulatory T-cell therapies market is projected to grow at an annualized rate of ~45%, till 2035.
Treg based therapies have become a research hotspot in the field of immunotherapy due to their ability to prevent / delay graft rejection and control autoimmune responses generated post adoptive transfer in vivo

Roots Analysis has announced the addition of “Regulatory T-Cell (Tregs) Therapies Market, 2021 – 2035” report to its list of offerings.

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
 A detailed assessment of the current market landscape of drug developers engaged in the development of regulatory T-cell therapies.
 A detailed analysis of more than 180+ completed, ongoing and planned clinical studies of regulatory T-cell therapies.
 Detailed profiles of developers of regulatory T-cell therapies (shortlisted on the basis of the number of pipeline products).
 An analysis of the partnerships that have been established in this domain, in the recent past.
 A detailed analysis of various investments undertaken by companies in this domain.
 A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

 Type of Product
 Tregs
 Interleukins
 Small molecules

 Target Indication
 Crohn’s Disease
 Bipolar Disorder
 Allergic Rhinoconjunctivitis
 COVID 19
 Diabetes Mellitus
 Systemic Lupus Erythematosus
 Alzheimer’s Disease
 Graft Vs Host Disease

 Key Geographical Regions
 North America
 Europe
 Asia Pacific

Key companies covered in the https://www.rootsanalysis....

 Abata Therapeutics
 Cellenkos
 Coya Therapeutics
 ILTOO Pharma
 NEKTAR
 Roche
 Sonoma Biotherapeutics
 TeraImmune
 TRACT Therapeutics

For more information please click on the following link:
https://www.rootsanalysis.... or email salesrootsanalysis.com

Other Recent Offerings
1. CD47 Targeting Therapeutics Market: Industry Trends and Global Forecasts, 2021-2030
2. Antibody Drug Conjugates Market (6th Edition): Industry Trends and Global Forecasts, 2021-2030
3. Novel T-Cell Immunotherapies Market: Industry Trends and Global Forecasts, 2021-2030
4. TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
5. Peptide Therapeutics Market: Industry Trends and Global Forecasts, 2021-2030
6. CRISPR Based Therapeutics Market: Focus on Cartridges, Syringes and Vials
7. (2nd Edition), 2021-2030

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnsonrootsanalysis.com
Steffan Joe @go_62036dc494e07
22 February, 07:45
PRE-STERILIZED / READY-TO-USE PRIMARY PACKAGING MARKET - CURRENT MARKET LANDSCAPE

Roots Analysis has announced the addition of Pre-Sterilized / Ready-to-Use Primary Packaging Market report to its list of offerings.

Presently, more than 150 pre-sterilized / RTU primary packaging systems, including cartridges, syringes and vials, as well as their respective closure systems are available worldwide. Majority (50%) of the pre-sterilized / RTU primary packaging systems are closures, followed by containers (34%) and container-closure systems (16%). It is worth highlighting that, of the total, 54 closures are suitable for use with vials, 19 are suitable for use with syringes and the remaining 5 are compatible with cartridges.

To request a sample copy / brochure of this report, please visit this – https://www.rootsanalysis....

Amongst the primary packaging containers, vials and syringes emerged as the most common types of pre-sterilized / RTU containers manufactured by stakeholders engaged in this domain. This can be attributed to the fact that these containers are the most suitable for packaging of small volume of therapeutics, such as biologics, cell therapies, small molecules, vaccines and other potent products.

Scope of the Report: -

The “Pre-Sterilized / Ready-to-Use Primary Packaging: Focus on Cartridges, Syringes and Vials (2nd Edition) - Market Distribution by Type of Packaging System (Vials, Syringes, Cartridges and Closures), Packaging Material (Glass and Plastic) and Key Geography (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa and Rest of the World) – Global Forecast 2021-2030” report features an extensive study of the current market landscape and future potential of ready-to-use primary packaging components, including cartridges, syringes and vials, and their respective closure systems (such as stoppers, needle shields and plungers) over the next decade. The study features an in-depth analysis of the key drivers and trends related to this domain. Amongst other elements, the report includes:
 A detailed assessment of the current market landscape of ready-to-use primary packaging components, featuring information on the type of container (vials, syringes, cartridges and others), type of fabrication material used (glass and plastic), sterilization technique used (ethylene oxide sterilization, steam sterilization, gamma irradiation, electron beam sterilization and dry heat sterilization), volume of container (less than 50 ml, 50 ml to 100 ml and more than 100 ml), compatible drug class (biologics and small molecules) and type of closure (stoppers, plungers, tip caps / needle shields, caps and seals). In addition, the chapter includes details related to ready-to-use packaging system manufacturers, along with information on their respective year of establishment, company size, location of headquarters and key players (in terms of number of offerings).
 A competitiveness analysis of ready-to-use primary packaging system manufacturers based on various relevant parameters, such as supplier power (based on the experience / expertise of the manufacturer) and key product specifications (type of container, type of fabrication material used, type of closure, sterilization technique used and compatible drug class).
 Elaborate profiles of prominent players engaged in the development of ready-to-use primary packaging systems. Each profile features a brief overview of the company, details related to its financials (if available), product portfolio, recent developments and an informed future outlook.
 An analysis of the partnerships that have been inked by stakeholders engaged in this domain, during the period 2015-2021, covering acquisitions, product / technology integration agreements, supply agreements, product / technology licensing agreements, product / technology development agreements, service alliances, distribution agreements and other relevant types of deals.
 An insightful discussion on the impact of the recent COVID-19 pandemic on the businesses of primary pharmaceutical packaging manufacturers. In addition, we have provided information on the strategic initiatives undertaken by pharmaceutical players to mitigate the challenges affiliated with the current global crisis.
 An in-depth analysis to estimate the current and future demand for ready-to-use container-closure systems based on various relevant parameters, such as type of packaging system and type of fabrication material used, across different regions, for the period 2021-2030.
 An elaborate discussion on the key trends (such as the advent of personalized / targeted therapies, shift towards more flexible packaging, rise of modular manufacturing facilities and advancement in robotic packaging solutions) that are likely to have an impact on the future adoption of ready-to-use packaging systems. It also features a Harvey ball analysis, highlighting the relative effect of each trend on the overall pharmaceutical packaging industry.
 A case study on the use of robotic machinery in pharmaceutical manufacturing and fill / finish operations, highlighting the advantages of using automation / automated technologies in such processes. Further, it presents the profiles of industry players that provide such equipment for aseptic processing of pharmaceuticals.

Key Questions Answered
 Who are the prominent players engaged in the global pre-sterilized / ready-to-use primary packaging market?
 What is the relative competitiveness of different ready-to-use primary packaging system manufacturers?
 Which partnership models are most commonly adopted by stakeholders engaged in this industry?
 How is the recent COVID-19 pandemic likely to impact the global ready-to-use primary packaging systems market?
 What is the current, global demand for ready-to-use containers and closures?
 What are the major market trends and driving factors that are
Steffan Joe @go_62036dc494e07
22 February, 07:40
The modular facilities market is estimated to be worth USD 6.4 billion in 2030, predicts Roots Analysis.

Off-site, modular construction minimizes disruption to building timelines and logistical delays, ensuring systematic delivery of new facilities, this is particularly beneficial within the healthcare industry, where speed, sanitation and sterility are crucial

Roots Analysis is pleased to announce the publication of its recent study, titled, “Modular Facilities in Pharmaceutical and Biotechnology Market”

To Request Sample Page - https://www.rootsanalysis....

The report features an extensive study of the current market landscape and future potential of the players engaged in offering services for modular facility construction for biotechnology and pharmaceutical industries. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features:

 An in-depth review of the market landscape of players that offer services for modular facility construction for biotechnology and pharmaceutical industries, along with the details of certifications obtained and COVID-19 related initiatives undertaken by modular service providers.
 A review of the market landscape of modular cleanrooms along with information on their year of establishment, company size, location of headquarters, type of industry served, type of modular cleanrooms, type of modular cleanroom components. It also includes details related to regulatory approvals and certifications.
 An analysis of the partnerships that have been inked by stakeholders in this domain, during the period between 2012 and 2021.
 An in-depth analysis of modular projects undertaken across key geographical regions, featuring information on type of facility, facility area, most active manufacturers, most active clients, location of facility.
 An insightful analysis on facility construction trends in the pharmaceutical industry for the last five years, highlighting facility construction projects established by top 20 pharma / biotech players.
 Elaborate profiles of key players that provide a wide range of modular manufacturing solutions to pharmaceutical and biotechnology industries.
 An in-depth review of emerging trends, including processing technologies with modular facilities, the shift towards smaller, multi-purpose modular facilities, and technological advancements in modular construction processes.
 A detailed discussion on the various growth drivers and trends related to modular solutions in emerging markets by pharmaceutical / biopharmaceutical CMOs.
 A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

For additional details, please visit - https://www.rootsanalysis....

 Type of Modular Construct
 Hybrid Skid
 Plug-and-Play
 Skid-Mounted
 Truckable
 Others
 Type of Construction Component
 Base Building
 Electrical System
 Mechanical System
 Process Equipment
 Process Piping
 Process Utilities
 Other Components
 Purpose of Facility
 Aseptic Filling
 Manufacturing
 Research and Development
 Others
 Facility Area
 Very Small
 Small
 Mid-Sized
 Large
 Very Large
 Scale of Operation
 Clinical
 Commercial
 Type of Industry
 Pharmaceutical
 Biotechnology
 Type of Product
 Biosimilars
 Cell and Gene Therapies
 Monoclonal Antibodies
 Vaccines
 Other Products
 Type of Facility
 New Facility
 Facility Expansions
 Key Geographical Regions
 North America
 Europe
 Asia
 Middle East and North Africa
 Latin America
 Rest of the World

Download Free Insights now - https://www.rootsanalysis....

Transcripts of interviews held with the following senior level representatives of stakeholder companies
Alan de Zayas (Modular Building Manufacturing and Construction Team, Avon Modular Construction)
 François Abiven (Executive Vice-President Global Business Unit BLS and Luca Mussati Vice President, Pharma and Biotech Life Sciences, Exyte)
 Maik Jornitz (President and Chief Executive Officer, G-CON Manufacturing)
 Pär Almhem (President, Modwave)
 Sulogna Roy (Ex Sales Manager, Zeton)
 Vernon Solomon (Specialist in Modular Design for Cleanrooms and Close Tolerance Temperature and Humidity Control, Environmental Systems Corporation)

Key companies covered in the report
 Cytiva
 G-CON Manufacturing
 Pharmadule Morimatsu
 NNE
 IPM Technologies
 KeyPlants
 Germfree Laboratories
 ModuleCO Pharma

For more information, please click on the following link
https://www.rootsanalysis....

You may also be interested in the following titles:
1. Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030
2. Biopharmaceutical CROs Market, 2021-2030
3. Continuous Manufacturing Equipment Providers Market, 2021-2030
4. DNA-Encoded Libraries: Platforms and Services Market
5. Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudharyrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Steffan Joe @go_62036dc494e07
22 February, 07:31
The cell therapy manufacturing market is growing at an annualized rate of 18%, claims Roots Analysis

Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry

London

Roots Analysis has announced the addition of “Cell Therapy Manufacturing Market (4th Edition), 2021-2030” report to its list of offerings.

Owing to the complex manufacturing processes, requirement of advanced production facilities and the growing demand for cell therapy products, developers are actively outsourcing certain manufacturing operations, in addition to expanding their in-house capabilities.

To order this 620 page report, which features 210+ figures and 280+ tables, please visit https://www.rootsanalysis....

Key Market Insights

Around 200 organizations claim to be engaged in cell therapy manufacturing
The market landscape is dominated by industry players, which constitute 65% of the total number of stakeholders. Amongst these, over 25% companies are large firms.

280+ production facilities dedicated to cell therapies have been established worldwide
North America has emerged as the manufacturing hub for cell therapies, with the presence of nearly 45% of the manufacturing facilities; this is followed by Europe (31%). Other emerging regions include China, Japan, South Korea and Australia.

90 cell therapy manufacturers are focused on immune cell and stem cell therapies
Most of the players in this domain are focused on manufacturing of T cell therapies, primarily CAR-T therapies, while the stem cell therapy manufacturers are primarily engaged in the production of adult stem cells and mesenchymal stem cell therapies

Presently, more than 70 companies carry out manufacturing at all scales of operation.
Nearly 45% players have the required capabilities for commercial scale manufacturing. It is worth noting that all the industry players manufacture cell therapies required for clinical purposes.

35+ companies offer automated and closed systems to cell therapy developers
More than 60 automated and closed systems are being used for cell therapy manufacturing. Organizations that are presently offering customized automated solutions for cell therapy processes / manufacturing are Fraunhofer Institute for Manufacturing Engineering and Automation IPA (Germany), KMC Systems (US), RoosterBio (US) and Mayo Clinic Center for Regenerative Medicine (US).

Several partnerships were established in this domain, during the period 2016-2021
More than 180 deals have been inked during the given time period. A large proportion (34%) of the partnerships were related to manufacturing of cell therapies, followed by acquisitions (17%) and licensing agreements (14%).

Expansion activity in this domain has grown at a CAGR of 59%, between 2016 and 2021
More than 75 facility expansions were reported during the given time period. Over 80% instances were related to the establishment of new facilities, followed by those involving the expansion of existing facilities (17%).

Role of big pharma players in this industry has evolved over the last few years; their initiatives increased at a CAGR of 41% during the period 2016-2020
Several big pharma players have undertaken various initiatives focused on cell therapy manufacturing. Gilead sciences, Takeda Pharmaceutical and Novartis are some of the prominent big pharma players in this domain.

The currently available global cell therapy manufacturing capacity is estimated to be over 1.88 billion sq. ft. of dedicated cleanroom area
The maximum (48%) installed capacity (in terms of cleanroom area) belongs to companies based in North America (48%); the region has higher number of players having multiple production facilities. This is followed by Asia Pacific (29%) and Europe (23%).

The demand for cell therapies is anticipated to grow at a CAGR of 22%, during 2021-2030
Presently, the clinical demand for stem cell and CAR-T cell-based products is the highest; this trend is unlikely to change in the foreseen future as well. On the other hand, the demand for tumor cell, NK cell and dendritic cell therapies is expected to grow at a relatively faster pace, over the next decade.

By 2030, the market for commercial scale cell therapy manufacturing is likely to grow at an annualized rate of 31.5%
Currently, North America and Europe capture more than 70% share of the overall market. Specifically, the cell therapy manufacturing market in Asia Pacific is driven by countries, such as China, Japan, South Korea, India and Singapore. It is worth noting that the current market in Asia Pacific is primarily driven by the clinical demand for cell therapies.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis....

The USD 14.5 billion (by 2030) financial opportunity associated with cell therapy manufacturing market has been analyzed across the following segments:
 Type of Cell Therapy
 T cell therapies
 Dendritic and tumor cell therapies
 NK cell therapies
 Stem cell therapies
 Other ATMPs

 Source of Cell
 Autologous
 Allogeneic

 Scale of Operation
 Clinical
 Commercial

 Purpose of Manufacturing
 In-house Manufacturing
 Contract Manufacturing

 Geographical Regions
 North America
 Europe
 Asia Pacific
 Rest of the World

The report also features inputs from eminent industry stakeholders, according to whom, the manufacturing of cell therapies is largely being outsourced due to exorbitant costs associated with the setting-up of in-house expertise. The report includes detailed transcripts of discussions held with the following experts:
 Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
 Gille
Steffan Joe @go_62036dc494e07
16 February, 09:59
The CD-47 targeting therapeutics market is projected to grow at an annualized rate of 42.9%, till 2035.
Roots Analysis has done a CD-47 Targeting Therapeutics Market, 2021-2035, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 100+ page report, which features 140+ figures and 170+ tables, please visit this link

Key Market Insights
 Presently, close to 80 CD-47 based drug candidates are being investigated across different phases of development for the treatment of a range of disease indications
 More than 40% of the therapies target CD-47 alone; majority of the pipeline candidates are currently in early stages of development
 A considerable increase in the partnership activity, witnessed over the past few years, indicates the steadily rising interest of stakeholders
 Foreseeing lucrative returns, many public and private investors have made investments worth USD 1.9 billion in 2020 alone, marking a surge in funding activity within the domain
 More than 7,000 patients have been recruited / enrolled in clinical trials, registered for this novel class of therapies, across different geographies
 A number of scientists, clinicians and industry veterans, affiliated to academic / medical / commercial organizations are spearheading research related to CD-47 based therapies
 Start-ups are driving the innovation; various R&D initiatives taken by these players have led to significant advancement in the development of several product candidates
 There has been a notable increase in published scientific literature related to the different types of CD-47 therapies; combined, these publications cover 100+ indications
 Companies are demonstrating the novelty of their proprietary CD-47 therapeutics, aiming to further enhance their respective offerings, both in terms of portfolio strength and diversity
 Driven by the growing cancer burden and rising need for targeted drug therapies, the CD-47 targeting therapies market is projected to grow at an annualized rate of more than 42% over the coming decade

For more information, please visit https://www.rootsanalysis....

Table Of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Key Historical Events related to CD47 Targeting Therapies
3.3. Application Areas
3.4. Mechanism of Action
3.5. Associated Side Effects and Likely Solutions
3.6. Key Features
3.7. Target Indications
3.8. Future Outlook

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. CD-47 Targeting Therapeutics: Market Landscape
4.2.1. Analysis by Type of Molecule
4.2.2. Analysis by Target Protein
4.2.3. Analysis by Type of Biologic
4.2.4. Analysis by Route of Administration
4.2.5. Analysis by Type of Molecule and Route of Administration
4.2.6. Analysis by Line of Treatment
4.2.7. Analysis by Phase of Development
4.2.8. Analysis by Therapeutic Area
4.2.9. Analysis by Target Indication
4.2.10. Analysis by Type of Therapy
4.3. CD-47 Therapeutics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Number of Pipeline Candidates
4.3.5. Analysis by Phase of Development
4.3.6 Analysis by Regional Strength
4.3.7. Analysis by Company Size and Location of Headquarters
4.3.8. Analysis by Year of Establishment, Company Size and Location of Headquarters

5. COMPANY PROFILES
5.1. Abpro
5.1.1. Company Overview
5.1.2. Financial Information
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook

5.2. ALX Oncology
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Product Portfolio
5.2.4. Recent Developments and Future Outlook

5.3. Apmonia Therapeutics
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Product Portfolio
5.3.4. Recent Developments and Future Outlook

5.4. Arch Oncology
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Product Portfolio
5.4.4. Recent Developments and Future Outlook

5.5. Aurigene
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Product Portfolio
5.5.4. Recent Developments and Future Outlook

5.6. Bristol Myers Squibb
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Product Portfolio
5.6.4. Recent Developments and Future Outlook

5.7. EpicentRx
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Product Portfolio
5.7.4. Recent Developments and Future Outlook

5.8. Forty Seven
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Product Portfolio
5.8.4. Recent Developments and Future Outlook

5.9. ImmuneOncia Therapeutics
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Product Portfolio
5.9.4. Recent Developments and Future Outlook

5.10. ImmuneOnco Biopharmaceuticals
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. Product Portfolio
5.10.4. Recent Developments and Future Outlook

5.11. Innovent Biologics
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. Product Portfolio
5.11.4. Recent Developments and Future Outlook

5.12. KAHR Medical
5.12.1. Company Overview
5.12.2. Financial Information
5.12.3. Product Portfolio
5.12.4. Recent Developments and Future Outlook

5.13. Light Chain Bioscience
5.13.1. Company Overview
5.13.2. Financial Information
5.13.3. Product Portfolio
5.13.4. Recent Developments and Future Outlook

5.14. Morphiex
5.14.1. Company Overview
5.14.2. Financial Information
5.14.3. Product Portfolio
5.14.4. Recent Developments and Future Outlook

5.15. Trillium Therapeutics
5.15.1. Company Overview
5.15.2. Financial Information
5.15.3. Product Portfolio
5.15.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overv
Steffan Joe @go_62036dc494e07
16 February, 09:51
The biopreservation media providers market is projected to grow at an annualized rate of 23.57%.

Roots Analysis has done a detailed study on “Biopreservation Media Providers Market, 2021-2035”, covering key aspects of the market’s evolution and identifying potential future growth opportunities.

To order this 230+ page report, which features 90+ figures and 100+ tables, please visit this link

Key Market Insights
 Presently, over 60 players claim to be engaged in providing biopreservation media.
 Over 190 biopreservation media are presently offered across the globe, intended for the preservation of biological samples at different preservation conditions.
 In order to build a competitive advantage, companies are focused on steadily improving the characteristics of their media offerings.
 The growing interest is also evident from the rise in partnership activity, a relatively larger proportion of the deals were signed by companies based in the US.
 Driven by the rising approval of temperature sensitive products, the market for biopreservation media providers is poised to grow at an annualized rate of 23.57%, till 2035.
 The projected market opportunity is likely to be well distributed across different end users, biological samples, packaging formats and key geographical regions.

For additional details, please visit
https://www.rootsanalysis....

Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY
2.1. Chapter Overview

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Biopreservation
3.3. Type of Biopreservation
3.3.1. Hypothermic Preservation
3.3.2. Cryopreservation

3.4. Applications of Biopreservation Media
3.5. Benefits and Limitations of Biopreservation Media
3.6. Concluding Remarks

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Biopreservation Media Providers: Service Providers Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Type of Company
4.2.4. Analysis by Location of Headquarters

4.3. Biopreservation Media: Market Landscape
4.3.1. Analysis by Preservation Condition
4.3.2. Analysis by Type of Serum
4.3.3. Analysis by Type of Biological Sample
4.3.4. Analysis by Area of Application
4.3.5. Analysis by Type of Packaging Format
4.3.6. Analysis by Packaging Volume
4.3.7. Analysis by Product Price

5. KEY INSIGHTS
5.1. Chapter Overview
5.2. Analysis by Location of Headquarters (World Map Representation)
5.3. Analysis by Year of Establishment, Company Size, Number of Biopreservation Media Offered and Region (4D Bubble Chart)
5.4. Analysis by Preservation Condition and Area of Application (Treemap Representation)
5.5. Analysis by Company Size, Region, Preservation Condition, Type of Serum and Type of Biological Sample (Grid Representation)
5.6. Analysis by Minimum Packaging Volume and Minimum Price (Heat Map Representation)

6. COMPANY COMPETITIVENESS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Benchmarking of Product Portfolio Strength
6.5. Benchmarking of Partnership Activity
6.6. Biopreservation Media Providers: Company Competitiveness Analysis
6.6.1. Company Competitiveness Analysis: Very Small Companies
6.6.2. Company Competitiveness Analysis: Small Companies
6.6.3. Company Competitiveness Analysis: Mid-Sized Companies
6.6.4. Company Competitiveness Analysis: Large Companies

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. BioLife Solutions
7.2.1. Company Overview
7.2.2. Recent Developments and Future Outlook

7.3. Cell Applications
7.3.1. Company Overview
7.3.2. Recent Developments and Future Outlook

7.4. HiMedia Laboratories
7.4.1. Company Overview
7.4.2. Recent Developments and Future Outlook

7.5. Merck
7.5.1. Company Overview
7.5.2. Recent Developments and Future Outlook

7.6. Thermo Fischer Scientific
7.6.1. Company Overview
7.6.2. Recent Developments and Future Outlook

7.7. United States Biological
7.7.1. Company Overview
7.7.2. Recent Developments and Future Outlook

7.8. ZenBio
7.8.1. Company Overview
7.8.2. Recent Developments and Future Outlook

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Biopreservation Media Providers: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.2.1. Analysis by Year and Type of Partnership
8.3.2.2. Analysis by Type of Partnership and Company Size

8.3.3. Analysis by Type of Partner
8.3.3.1. Analysis by Year of Partnership and Type of Partner
8.3.3.2. Analysis by Type of Partner and Type of Partnership
8.3.3.3. Analysis by Type of Partner and Company Size

8.3.4. Most Active Players: Analysis by Number of Partnerships
8.3.5. Regional Analysis
8.3.5.1. Local and International Deals
8.3.5.2. Intercontinental and Intracontinental Deals
8.3.5.3. Analysis by Location of Headquarters of Partner
8.3.5.4. Analysis by Location of Headquarters of Partner and Type of Partnership

9. BOWMAN CLOCK PRICING STRATEGY
9.1. Chapter Overview
9.2. Bowman Strategy Clock
9.2.1. Two Dimensions of Bowman Strategy Clock
9.2.2. Eight Positions on Bowman Strategy Clock

9.3. Roots Analysis Framework
9.3.1. Methodology
9.3.2. Theoretical Framework and Price Evaluation Hypothesis
9.3.3. Results and Interpretation
9.3.3.1. Bowman Clock Pricing Strategy Graphical Representation
9.3.3.2. Product Price Evaluation Matrix: Information on Preservation Condition
9.3.3.3. Product Price Evaluation Matrix: Information on Type of Serum
9.3.3.4. Product Price Evaluation Matrix: Information on Type of Biological Sample
9.3.3.5. Product Price Evaluation Matrix: Information on Minimum Packaging Volume
9.3.3.6. Product Price Evaluation
Steffan Joe @go_62036dc494e07
16 February, 09:09
At-home blood collection and micro sampling devices market is projected to grow at a CAGR of 10.7 %.
Roots Analysis has done a detailed study on At-Home Blood Collection and Micro Sampling Devices market, 2021-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 190 page report, which features 95+ figures and 110+ tables, please visit https://www.rootsanalysis....

Key Market Insights
 The ongoing COVID-19 pandemic has accelerated the pace at which the healthcare sector is evolving, thereby, spurring innovations that allow patients to collect blood samples at-home as well as monitor their health remotely
 Presently, close to 50 at-home blood collection and micro sampling devices are available / being developed; majority of the firms engaged in this domain are start ups or small companies located in the US
 Most of the at-home devices intended for collection of whole capillary blood are presently marketed; DBS technology, used for preparation of dried blood spot cards, has emerged as the most popular platform
 In pursuit of gaining a competitive edge, stakeholders are actively expanding their product portfolios and upgrading their devices, via incorporation of advanced features
 Over the years, the intellectual property related to blood collection devices has grown at a commendable pace, with majority of the patents being filed by industry players
 The growing interest of the stakeholders is also reflected from the recent rise in partnership activity; a significant proportion of the deals inked till date were focused on market expansion
 To support the ongoing innovation in this domain, private and public investors have made substantial capital investments, worth ~USD 650 million, in initiatives of various industry stakeholders
 Given the favourable increase in adoption of at-home blood collection and micro sampling devices during the COVID-19 pandemic, the market is anticipated to witness significant growth in the foreseen future

For more information, please visit https://www.rootsanalysis....

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of At-Home Blood Collection and Micro Sampling Devices
3.3. Applications of Blood Sampling and Testing
3.3.1. Complete Blood Count
3.3.2. Basic Metabolic Panel
3.3.3. Lipoprotein Panel
3.4. Types of Blood Sampling
3.4.1. Dried Blood Sampling
3.4.2. Wet Blood Sampling

3.5. Benefits of At-Home Blood Collection
3.6. Methods Used for At-Home Blood Collection
3.6.1. Fingerstick Method
3.6.2. Press Button Method
3.6.3. Heel-stick Method
3.7. Types of At-Home Blood Collection and Micro Sampling Devices
3.7.1. Dried Blood Spot Collection Kits
3.7.2. Microtainer Tubes

3.8. Future Perspectives

4. MARKET OVERVIEW
4. Market Overview
4.1. Chapter Overview
4.2. At-Home Blood Collection and Micro Sampling Devices: Overall Market Landscape
4.2.1. Analysis by Device Class
4.2.2. Analysis by Current Status of Development
4.2.3. Analysis by Regulatory Approvals / Certifications Received
4.2.4. Analysis by Type of Technology
4.2.5. Analysis by Device Usage
4.2.6 Analysis by Type of Sample
4.2.7. Analysis by Blood Sample State
4.2.8. Analysis by Volume of Sample Collected
4.2.9. Analysis by Puncture Site
4.2.10. Analysis by Method of Sample Collection
4.2.11. Analysis by Storage Temperature
4.2.12. Analysis by Application Area

4.3. At-Home Blood Collection and Micro Sampling Devices: List of Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Geography
4.3.4. Analysis by Year of Establishment, Company Size and Location of Headquarters
4.4. Most Active Players: Analysis by Number of Products

5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Input Parameters
5.3. Methodology
5.3.1. Product Competitiveness Analysis: North America
5.3.2. Product Competitiveness Analysis: Europe
5.3.3. Product Competitiveness Analysis: Asia-Pacific

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. EUROIMMUN
6.2.1. Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook

6.3. Everlywell
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook

6.4. Labcorp
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook

6.5. Labonovum
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook

6.6. Lameditech
6.6.1. Company Overview
6.6.2. Product Portfolio
6.6.3. Recent Developments and Future Outlook

6.7. Quest Diagnostics
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook

6.8. Spot On Sciences
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3. Recent Developments and Future Outlook

6.9. Tasso
6.9.1. Company Overview
6.9.2. Product Portfolio
6.9.3. Recent Developments and Future Outlook

6.10. Weavr Health
6.10.1. Company Overview
6.10.2. Product Portfolio
6.10.3. Recent Developments and Future Outlook

6.11. YourBio Health
6.11.1. Company Overview
6.11.2. Product Portfolio
6.11.3. Recent Developments and Future Outlook

7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. At-Home Blood Collection and Micro Sampling Devices: Patent Analysis
7.2.1. Scope and Methodology
7.2.2. Analysis by Publication Year
7.2.3. Analysis by Publication Year and Type of Patent
7.2.4. Analysis by Geography
7.2.5. Analysis by CPC Symbols
7.2.6. Analysis by Emerging Focus Area
7.2.7. Most Active Players: Analysis by Num
Steffan Joe @go_62036dc494e07
09 February, 10:43
Top Selling Biologics Market, 2021-2030

To order this 320+ page report, please visit this link

Key Inclusions
 A detailed assessment of the current market landscape of top selling biologics, along with information on developers (such as year of establishment, company size, location of headquarters and current portfolio of top selling biologics), type of biologic, route of administration, target gene / antigen, type of packaging format, disease indication and target therapeutic area.

 It also provides an in-depth analysis of key therapeutic areas, such as oncological disorders, metabolic disorders, autoimmune disorders, gastrointestinal disorders, ophthalmic disorders, CNS/ Neurological disorders, cardiovascular disorders, blood disorders, respiratory disorders, bone disorders and others, in companies that are engaged in the development of top selling biologics.

 A detailed analysis of revenues generated by top selling biologics (60+) between 2016 and 2020. It includes information on reasons for significant increase / decrease in their sales in the given time span. It also includes the analysis of revenues generated by top selling biologics in 2020, based on several relevant parameters, such as type of biologic and developer.
 An analysis of the completed, ongoing, and planned clinical studies for top selling biologics. The trials considered in the analysis were analyzed based on several relevant parameters, such as trial registration year, trial recruitment status, enrolled patient population, study design, target therapeutic area, geographical location of trials and leading organizations. It is worth highlighting that these studies were registered to evaluate the already approved top selling biologics for potential combinations, device evaluations and comparisons.
 A detailed analysis on the key promotional strategies that are being / have been adopted by developers of top selling biologics. It further includes a detailed Harvey ball analysis highlighting the extent of promotional content on product websites of all biologics (60+) that fall into this criterion. Additionally, it features detailed profiles, presenting promotional strategies implemented for top 7 blockbuster biologics (in terms of revenues), along with information on their promotional content on product websites (covering key messages for patients and healthcare professionals), details of patient support programs and a brief section on DTC advertisements.
 A brief analysis of the product lifecycle management strategies, such as geographical expansion, approval for additional disease indications, reformulations, combination therapies, exploiting alternate routes of administration reimbursement programs and pricing strategies, that have been adopted by stakeholders engaged in the development of top selling biologics, during the period 2016-2020. The information in detail has been provided for top 10 biologics (in terms of revenues).
 An elaborate analysis representing annual treatment cost of top selling biologics. It includes grid representations, providing information on 60+ top selling biologics, based on type of biologic.

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
 Type of Biologic
 Monoclonal Antibodies
 Hormones
 Fusion Proteins
 Enzymes
 Interferons
 Antibody Fragments
 Gene Therapies
 Vaccines

 Key Developers
 Genentech / Roche
 AbbVie
 Janssen Biotech / Johnson & Johnson
 Amgen
 Eli Lilly
 Bristol Myers Squibb
 Sanofi
 Novo Nordisk
 Regeneron

To request sample pages, please visit this link

Key Questions Answered
 Which biologics are likely to attain the blockbuster status in the foreseen future?
 Who are the leading players engaged in the development of top selling biologics?
 Which key clinical conditions are presently targeted by top selling biologics?
 What are the historical global sales of top selling biologics?
 Which are the most commonly adopted product life cycle management strategies by players for their top selling products?
 What is the current annual treatment cost associated with top selling biologics?
 Which regions have emerged as the key hubs for conducting clinical studies focused on top selling biologics?
 How has the biosimilars landscape in this market evolved over the past few years?
 Which factors are likely to influence the evolution of this market?
 How is the current and future market opportunity likely to be distributed across key market segments?

You may also be interested in the following titles:
1. Novel T-Cell Immunotherapies Market, 2021-2030
2. TIL-based Therapies Market, 2021-2030
3. Non-Hormonal Therapies Market, 2021-2030
4. Gene Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030
5. Global T-Cell Therapies Market (5th Edition): Industry Trends and Global Forecasts, 2021-2030

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnsonrootsanalysis.com
Steffan Joe @go_62036dc494e07
09 February, 10:39
The top selling biologics market, claims Roots Analysis
Biologics represent the cutting edge of medical research, offering hope to patients with clinical conditions that were previously considered incurable; 6 of the top 10 best selling drugs are biotherapeutics

Roots Analysis is pleased to announce the publication of its recent study, titled, “Top Selling Biologics Market, 2021 – 2030”

The report features an extensive study of the current market landscape and future potential of the top selling biologics available for the treatment of a variety of disease indications. The study includes an in-depth analysis, highlighting the key initiatives undertaken by various stakeholders engaged in this domain. Amongst other elements, the study includes:
 A detailed assessment of the current market landscape of top selling biologics
 A detailed analysis of revenues generated by top selling biologics
 An analysis of the completed, ongoing, and planned clinical studies for top selling biologics
 A detailed analysis on the key promotional strategies that are being / have been adopted by developers of top selling biologics
 A brief analysis of the product lifecycle management strategies
 An elaborate analysis representing annual treatment cost of top selling biologics.
 A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
 Type of Biologic
 Monoclonal Antibodies
 Hormones
 Fusion Proteins
 Enzymes
 Interferons
 Antibody Fragments
 Gene Therapies
 Vaccines
 Key Developers
 Genentech / Roche
 AbbVie
 Janssen Biotech / Johnson & Johnson
 Amgen
 Eli Lilly
 Bristol Myers Squibb
 Sanofi
 Novo Nordisk
 Regeneron

Key companies covered in the report
 Bristol Myers Squibb
 AbbVie
 Alexion Pharmaceuticals
 Allergan
 Amgen
 AstraZeneca
 Bayer
 Biogen
 BioMarin
 Bristol-Myers Squibb
 Chugai Pharmaceutical
 Daiichi Sankyo
 Eli Lilly
 Genentech
 GlaxoSmithKline
 ImClone
 IMMUNEX
 Janssen Biotech
 Johnson & Johnson
 MedImmune
 Merck
 Novartis
 Novo Nordisk
 Regeneron Pharmaceuticals
 Roche
 Sanofi
 Torii Pharmaceutical
 UCB
 Vifor Pharma

For more information, please click on the following link:
https://www.rootsanalysis....

Other Recent Offerings
1. Novel T-Cell Immunotherapies Market, 2021-2030
2. TIL-based Therapies Market, 2021-2030
3. Non-Hormonal Therapies Market, 2021-2030
4. Gene Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030
5. Global T-Cell Therapies Market (5th Edition): Industry Trends and Global Forecasts, 2021-2030

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnsonrootsanalysis.com
Steffan Joe @go_62036dc494e07
09 February, 10:34
Biologics market is projected to be worth USD 156 billion by 2030.
Owing to the numerous benefits offered by biologics, this drug class has become an integral part of the overall pharmaceutical industry, having captured a significant market share over the past couple of decades

Roots Analysis has announced the addition of the “Top Selling Biologics Market, 2021 – 2030” report to its list of offerings.

Over the years, around 200 biologics have been approved for the treatment of various disease indications in the US and Europe. In 2020, 18 new biologics received approval by the USFDA. Despite their complex and cost intensive manufacturing protocols, biopharmaceuticals (once approved) are considered to be highly profitable assets. In the recent past, many biological interventions have achieved blockbuster status (in some cases, registering revenues worth over USD 4 billion a year); prominent examples include (arranged in decreasing order of 2020 revenues) Humira®, Keytruda®, Stelara®, Opdivo®, Avastin®, Trulicity®, Enbrel®, Ocrevus™ and Rituxan®.

To order this 320+ page report, which features 190+ figures and 195+ tables, please visit this https://www.rootsanalysis....
Key Market Insights
More than 65 top selling biologics (revenues equal to or above USD 500 million in 2020) are currently available in the market
Majority (54%) of the aforementioned candidates are monoclonal antibodies, followed by hormones (19%) and enzymes (9%). Further, subcutaneous route (50%) emerged as the most preferred route of administration for such therapies, followed by the intravenous route (40%).

More than 50% the developers of top selling biologics are based in North America
The top selling biologics market is currently dominated by the presence of large companies (82%). Additionally, majority of such players were established before the year 2000.

Over 2,450 clinical trials registered for the evaluation of top selling biologics, till Q3 2020
Of the total, 1,892 trials were registered for the evaluation of products targeting oncological disorders, followed by those investigating biologics intended for the treatment of metabolic disorders (122) and autoimmune disorders (98).

Around 250 biosimilars of top selling biologics are currently approved / under development
Close to 30% of the aforementioned candidates have already been approved. It is worth mentioning that over 100 biosimilars have received approval in Asia Pacific. Within this region, India and South Korea emerged as key hubs, having granted maximum approvals for biosimilars of top selling biologics (in terms of 2020 revenues).

Monoclonal antibodies are anticipated to capture over 75% of the market share by 2030
Over 40% of the market share is anticipated to be capture by Genentech / Roche and Merck by 2030. It is worth mentioning that as the patents of the currently marketed products have already / are expected to expire towards the end of the forecast period, the market is likely to reach maturity.

To request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis....
Key Questions Answered
 Which biologics are likely to attain the blockbuster status in the foreseen future?
 Who are the leading players engaged in the development of top selling biologics?
 Which key clinical conditions are presently targeted by top selling biologics?
 What are the historical global sales of top selling biologics?
 Which are the most commonly adopted product life cycle management strategies by players for their top selling products?
 What is the current annual treatment cost associated with top selling biologics?
 Which regions have emerged as the key hubs for conducting clinical studies focused on top selling biologics?
 How has the biosimilars landscape in this market evolved over the past few years?
 Which factors are likely to influence the evolution of this market?
 How is the current and future market opportunity likely to be distributed across key market segments?

The USD 156 billion (by 2030) financial opportunity associated with the top selling biologics market has been analyzed across the following segments:
Type of Biologic
 Monoclonal Antibodies
 Hormones
 Fusion Proteins
 Enzymes
 Interferons
 Antibody Fragments
 Gene Therapies
 Vaccines

Key Developers
 Genentech / Roche
 AbbVie
 Janssen Biotech / Johnson & Johnson
 Amgen
 Eli Lilly
 Bristol Myers Squibb
 Sanofi
 Novo Nordisk
 Regeneron

For additional details, please visit
https://www.rootsanalysis.... or email salesrootsanalysis.com

You may also be interested in the following titles:
1. Novel T-Cell Immunotherapies Market, 2021-2030
2. TIL-based Therapies Market, 2021-2030
3. Non-Hormonal Therapies Market, 2021-2030
4. Gene Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030
5. Global T-Cell Therapies Market (5th Edition): Industry Trends and Global Forecasts, 2021-2030

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnsonrootsanalysis.com